Understanding how Myct1 affects blood vessel growth and immune response in cancer
Official title: Myct1 control of the angioimmune interface
Funded at Washington University · NIH-11093939 · Data updated 2026-11-12
This study is looking at a protein called Myct1 to see how it helps control blood vessel growth and immune responses in tumors, which could lead to better cancer treatments that limit blood vessel formation while boosting the body's immune attack on cancer cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | June 9, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $545,472 |
| NIH project number | 5R01CA271714-03 |
| Project ID | NIH-11093939 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who may benefit from therapies that target angiogenesis and enhance immune cell activity.
✕Less likely to help
Patients with non-cancerous conditions or those whose tumors do not involve angiogenesis may not receive benefit from this research.
What this research studies
This research investigates the role of Myct1, a protein found in endothelial cells, in regulating blood vessel formation and immune responses in tumors. By studying genetically modified mice and human cancer samples, the researchers aim to understand how Myct1 influences both angiogenesis and the activity of immune cells, particularly CD8+ T lymphocytes. The approach includes using knockout models and treatments with antibodies to explore the potential for improved cancer therapies that reduce blood vessel growth while enhancing immune response against tumors.
Why it matters
Potential benefit: If successful, this research could lead to new cancer treatments that effectively control tumor growth by targeting blood vessel formation and boosting the immune response.
How similar studies have gone: Previous research has shown promising results in targeting angiogenesis and enhancing immune responses in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Choi, Kyunghee — Washington University
- Study coordinator: Choi, Kyunghee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.